Navigation Links
GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
Date:2/20/2009

ATLANTA, Feb. 20 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based, publicly traded biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, announced the first injections in its Phase 2a Human Clinical Vaccine Trial for its candidate HIV/AIDS vaccine. The trial, designated HVTN 205, is being conducted by the HIV Vaccine Trials Network (HVTN). The HVTN, funded and supported by the National Institutes of Allergy and Infectious Diseases (NIAID), is the largest worldwide clinical trials network dedicated to the development and testing of HIV/AIDS vaccines. The HVTN has sponsored over 80 Phase 1 trials for the initial evaluation of safety and immunogenicity of candidate HIV/AIDS vaccines. The results of these trials have merited only five phase 2a trials since 1992. Progressing to Phase 2 is a significant step for GeoVax. The Company is pleased to report that the first injections for the Phase 2a trial were conducted at the HVTN network sites at the University of Alabama, Birmingham, and Vanderbilt University, Nashville.

The trial will include a total of 225 volunteers (150 vaccine recipients and 75 placebo recipients) and take place at 13 HVTN sites: 11 in North America and 2 in South America. Sites in the United States include Emory University, Atlanta; Harvard Medical School, Boston; Vanderbilt University, Nashville; University of Rochester; Fred Hutchinson Cancer Research Center, Seattle; the San Francisco Department of Public Health; University of Alabama, Birmingham and sites at Columbia University, Union Square, and the Bronx in New York City. In South America, participants are to be enrolled in Peru at sites in Iquitos and Miraflores (Lima).

"I am extremely pleased that our vaccine meri
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. GeoVaxs Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America
2. GeoVax Reports Progress on Its AIDS Vaccine Technology
3. GeoVax Secures $10 Million Financing Commitment
4. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
5. GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials
6. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
7. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
8. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
9. GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update
10. Excellent Results Received from GeoVaxs Full-Dose HIV/AIDS Vaccine Trial
11. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... ZIONA, Israel , June 29, ... BVXV, TASE: BVXV) today announced positive preliminary results from ... candidate for a universal influenza vaccine. In this trial, ... of 50 to 65, followed by an administration of ... later. M-001 was found to be safe and well ...
(Date:6/29/2015)... Calif. , June 29, 2015  Isis Pharmaceuticals, ... has been added to the Russell 1000 Index, effective ... performance of the large-cap segment of the U.S. equity ... Index and includes approximately 1000 of the largest securities ... current index membership. "We are pleased to ...
(Date:6/29/2015)... Calif. , June 29, 2015  Arbor ... medical workstation lineup. The high-powered, multi-functional M2150 ... generation Intel® Haswell Core i5-4402E 1.6 ... provide significant data processing and computing performance. Integrated ... making the unit well suited for graphics-intense applications ...
Breaking Medicine Technology:BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
... , CHEYENNE, Wyo., Aug. 24 The ... of its Pay-for-Participation (P4P) program, a component of its innovative ... collaboration between the practitioner community and the Wyoming EqualityCare (EC) ... Wyoming Medicaid members. , , (Logo: ...
... Curemark Founder and CEO Dr. Joan Fallon delivered the ... Conference at Harvard Medical School on July 14th. , ... conclave is particularly significant, since epigenetics is the study of ... in the DNA sequence. Presenters at the session showcased many ...
Cached Medicine Technology:Wyoming Department of Health's Pay-for-Participation Program Reports Positive Clinical Outcomes 2Wyoming Department of Health's Pay-for-Participation Program Reports Positive Clinical Outcomes 3Curemark CEO Presents at Epigenomics Conference 2
(Date:6/29/2015)... (PRWEB) , ... June 29, 2015 , ... ... have developed a new approach to build nearly complete genomes by combining high-throughput ... of genomic variation, critically important for their association with human disease, but previously ...
(Date:6/29/2015)... (PRWEB) , ... June 29, 2015 , ... ... to healthcare providers for patients with certain neuropsychiatric and chronic pain conditions, has ... and CEO. , The appointments include: Peter Donato, Senior Vice President, Chief Financial ...
(Date:6/29/2015)... ... ... OR Manager announced Monday the launch of an enhanced http://www.ormanager.com . The ... and weekly eLetter. The website contains the same informational articles, products, and resources that ... , In addition to a refreshed look, http://www.ormanager.com now provides users with ...
(Date:6/29/2015)... York, NY (PRWEB) , ... June 29, 2015 ... ... dietary supplement with Citicoline (Cognizin®) from Kyowa Hakko Bio to French consumers. , ... the macular cells from oxidative stress caused by free radicals. In addition to ...
(Date:6/29/2015)... ... June 29, 2015 , ... FACE is proud to be one of ... reduction of the double chin and redefining of the jawline. Excess fat under ... older and heavier causing the person distress and poor self-image. , Kybella was produced ...
Breaking Medicine News(10 mins):Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 2Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 3Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 4Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 2Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 3Health News:OR Manager Launches New Website 2Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 2Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 3Health News:FACE Detroit Skin and Wellness Clinic Introduces Newly FDA Approved Kybella for the elimination of the Double Chin. 2
... ... Best Nursing Homes” List , ... Tucson, Ariz. (Vocus) February 2, 2010 -- A Tucson retirement community’s health ... by U.S. News and World Report. The designation will appear in the national magazine’s ...
... , INDIANAPOLIS , Feb. 2 ... senior management is scheduled to present at the UBS 20th Annual ... 8:00 a.m. Eastern Standard Time .   , All interested ... by visiting www.wellpoint.com and selecting the "Investor ...
... the University of Pennsylvania School of Medicine have found ... a toxic form of the same protein. The protein, ... that are the hallmarks of Parkinson,s disease, Alzheimer,s disease, ... molecular link between the presence of inclusions and neuronal ...
... study found , TUESDAY, Feb. 2 (HealthDay News) -- ... who are at risk for kidney failure and associated problems, ... in the Feb. 3 issue of the Journal of ... for protein levels in urine (proteinuria) be incorporated into upcoming ...
... , SOMERSET, N.J. , Feb. 2 ... logistical staffing provider serving the Federal Government, today announced that it ... the Company has regained compliance with the $1.00 per ... Nasdaq Capital Market, pursuant to the Nasdaq Marketplace Rules. In the ...
... link between MMR vaccine, developmental disorder , TUESDAY, ... journal The Lancet on Tuesday formally retracted ... mumps and rubella vaccine to autism and gastrointestinal problems. ... 1998, set off a worldwide furor, with many researchers ...
Cached Medicine News:Health News:U.S. News & World Report Ranks Sonora at Splendido Among Top in Nation 2Health News:WellPoint Announces Appearance at Upcoming Conference 2Health News:WellPoint Announces Appearance at Upcoming Conference 3Health News:3 brain diseases linked by toxic form of same neural protein 2Health News:Protein Levels in Urine Help Predict Kidney Function 2Health News:Protein Levels in Urine Help Predict Kidney Function 3Health News:TeamStaff Regains Compliance with Nasdaq $1.00 Minimum Bid Rule 2Health News:TeamStaff Regains Compliance with Nasdaq $1.00 Minimum Bid Rule 3Health News:Controversial Autism Study Retracted by Medical Journal 2Health News:Controversial Autism Study Retracted by Medical Journal 3Health News:Controversial Autism Study Retracted by Medical Journal 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: